Anni Nørgaard Jeppesen, Christophe Duez, Hans Kirkegaard, Anders Morten Grejs, Anne-Mette Hvas
{"title":"低温治疗的心脏骤停患者纤维蛋白溶解。","authors":"Anni Nørgaard Jeppesen, Christophe Duez, Hans Kirkegaard, Anders Morten Grejs, Anne-Mette Hvas","doi":"10.1089/ther.2022.0037","DOIUrl":null,"url":null,"abstract":"<p><p>Hypothermia affects coagulation, but the effect of hypothermia on fibrinolysis is not clarified. Imbalance in the fibrinolytic system may lead to increased risk of bleeding or thrombosis. Our aim was to investigate if resuscitated cardiac arrest patients treated with hypothermia had an unbalanced fibrinolysis. A prospective cohort study, including 82 patients were treated with hypothermia at 33°C ± 1°C after out-of-hospital cardiac arrest. Blood samples were collected at 24 hours (hypothermia) and at 72 hours (normothermia). Samples were analyzed for fibrin D-dimer, tissue plasminogen activator (tPA), plasminogen, plasminogen activator Inhibitor-1 (PAI-1), thrombin-activatable fibrinolysis inhibitor (TAFI), and an in-house dynamic fibrin clot formation and lysis assay.Compared with normothermia, hypothermia significantly increased plasminogen activity (mean difference = 10.4%, 95% confidence interval [CI] 7.9-12.9), <i>p</i> < 0.001), PAI-1 levels (mean difference = 275 ng/mL, 95% CI 203-348, <i>p</i> < 0.001), and tPA levels (mean difference = 1.0 ng/mL, 95% CI 0.2-1.7, <i>p</i> = 0.01). No differences between hypothermia and normothermia were found in TAFI activity (<i>p</i> = 0.59) or in the fibrin D-dimer levels (<i>p</i> = 0.08). The fibrin clot lysis curves showed three different patterns: normal-, flat-, or resistant clot lysis curve. At hypothermia 45 (55%) patients had a resistant clot lysis curve and 33 (44%) patients had a resistant clot lysis curve at normothermia (<i>p</i> = 0.047). Comatose, resuscitated, cardiac arrest patients treated with hypothermia express an inhibited fibrinolysis even after rewarming. This could potentially increase the thromboembolic risk. ClinicalTrials.gov ID: NCT02258360.</p>","PeriodicalId":22972,"journal":{"name":"Therapeutic hypothermia and temperature management","volume":"13 3","pages":"112-119"},"PeriodicalIF":0.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Fibrinolysis in Cardiac Arrest Patients Treated with Hypothermia.\",\"authors\":\"Anni Nørgaard Jeppesen, Christophe Duez, Hans Kirkegaard, Anders Morten Grejs, Anne-Mette Hvas\",\"doi\":\"10.1089/ther.2022.0037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hypothermia affects coagulation, but the effect of hypothermia on fibrinolysis is not clarified. Imbalance in the fibrinolytic system may lead to increased risk of bleeding or thrombosis. Our aim was to investigate if resuscitated cardiac arrest patients treated with hypothermia had an unbalanced fibrinolysis. A prospective cohort study, including 82 patients were treated with hypothermia at 33°C ± 1°C after out-of-hospital cardiac arrest. Blood samples were collected at 24 hours (hypothermia) and at 72 hours (normothermia). Samples were analyzed for fibrin D-dimer, tissue plasminogen activator (tPA), plasminogen, plasminogen activator Inhibitor-1 (PAI-1), thrombin-activatable fibrinolysis inhibitor (TAFI), and an in-house dynamic fibrin clot formation and lysis assay.Compared with normothermia, hypothermia significantly increased plasminogen activity (mean difference = 10.4%, 95% confidence interval [CI] 7.9-12.9), <i>p</i> < 0.001), PAI-1 levels (mean difference = 275 ng/mL, 95% CI 203-348, <i>p</i> < 0.001), and tPA levels (mean difference = 1.0 ng/mL, 95% CI 0.2-1.7, <i>p</i> = 0.01). No differences between hypothermia and normothermia were found in TAFI activity (<i>p</i> = 0.59) or in the fibrin D-dimer levels (<i>p</i> = 0.08). The fibrin clot lysis curves showed three different patterns: normal-, flat-, or resistant clot lysis curve. At hypothermia 45 (55%) patients had a resistant clot lysis curve and 33 (44%) patients had a resistant clot lysis curve at normothermia (<i>p</i> = 0.047). Comatose, resuscitated, cardiac arrest patients treated with hypothermia express an inhibited fibrinolysis even after rewarming. This could potentially increase the thromboembolic risk. ClinicalTrials.gov ID: NCT02258360.</p>\",\"PeriodicalId\":22972,\"journal\":{\"name\":\"Therapeutic hypothermia and temperature management\",\"volume\":\"13 3\",\"pages\":\"112-119\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic hypothermia and temperature management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/ther.2022.0037\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic hypothermia and temperature management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ther.2022.0037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 1
摘要
低温影响凝血,但低温对纤溶的影响尚不清楚。纤溶系统失衡可能导致出血或血栓形成的风险增加。我们的目的是调查是否复苏的心脏骤停患者接受低温治疗有不平衡的纤维蛋白溶解。一项前瞻性队列研究,包括82例院外心脏骤停后33°C±1°C低温治疗的患者。在24小时(体温过低)和72小时(体温正常)采集血样。分析样品的纤维蛋白d -二聚体、组织纤溶酶原激活剂(tPA)、纤溶酶原、纤溶酶原激活剂抑制剂-1 (PAI-1)、可凝血酶激活的纤维蛋白溶解抑制剂(TAFI),以及内部动态纤维蛋白凝块形成和溶解试验。与常温相比,低温显著增加纤溶酶原活性(平均差异为10.4%,95%可信区间[CI] 7.9 ~ 12.9), p p p = 0.01)。在TAFI活性(p = 0.59)和纤维蛋白d -二聚体水平(p = 0.08)方面,低温和常温之间没有差异。纤维蛋白凝块溶解曲线显示三种不同的模式:正常、平坦或抵抗性凝块溶解曲线。在低温条件下,45例(55%)患者出现抵抗性凝块溶解曲线,而在常温下,33例(44%)患者出现抵抗性凝块溶解曲线(p = 0.047)。经低温治疗的昏迷、复苏、心脏骤停患者即使在复温后也表现出受抑制的纤维蛋白溶解。这可能会增加血栓栓塞的风险。ClinicalTrials.gov ID: NCT02258360。
Fibrinolysis in Cardiac Arrest Patients Treated with Hypothermia.
Hypothermia affects coagulation, but the effect of hypothermia on fibrinolysis is not clarified. Imbalance in the fibrinolytic system may lead to increased risk of bleeding or thrombosis. Our aim was to investigate if resuscitated cardiac arrest patients treated with hypothermia had an unbalanced fibrinolysis. A prospective cohort study, including 82 patients were treated with hypothermia at 33°C ± 1°C after out-of-hospital cardiac arrest. Blood samples were collected at 24 hours (hypothermia) and at 72 hours (normothermia). Samples were analyzed for fibrin D-dimer, tissue plasminogen activator (tPA), plasminogen, plasminogen activator Inhibitor-1 (PAI-1), thrombin-activatable fibrinolysis inhibitor (TAFI), and an in-house dynamic fibrin clot formation and lysis assay.Compared with normothermia, hypothermia significantly increased plasminogen activity (mean difference = 10.4%, 95% confidence interval [CI] 7.9-12.9), p < 0.001), PAI-1 levels (mean difference = 275 ng/mL, 95% CI 203-348, p < 0.001), and tPA levels (mean difference = 1.0 ng/mL, 95% CI 0.2-1.7, p = 0.01). No differences between hypothermia and normothermia were found in TAFI activity (p = 0.59) or in the fibrin D-dimer levels (p = 0.08). The fibrin clot lysis curves showed three different patterns: normal-, flat-, or resistant clot lysis curve. At hypothermia 45 (55%) patients had a resistant clot lysis curve and 33 (44%) patients had a resistant clot lysis curve at normothermia (p = 0.047). Comatose, resuscitated, cardiac arrest patients treated with hypothermia express an inhibited fibrinolysis even after rewarming. This could potentially increase the thromboembolic risk. ClinicalTrials.gov ID: NCT02258360.
期刊介绍:
Therapeutic Hypothermia and Temperature Management is the first and only journal to cover all aspects of hypothermia and temperature considerations relevant to this exciting field, including its application in cardiac arrest, spinal cord and traumatic brain injury, stroke, burns, and much more. The Journal provides a strong multidisciplinary forum to ensure that research advances are well disseminated, and that therapeutic hypothermia is well understood and used effectively to enhance patient outcomes. Novel findings from translational preclinical investigations as well as clinical studies and trials are featured in original articles, state-of-the-art review articles, protocols and best practices.
Therapeutic Hypothermia and Temperature Management coverage includes:
Temperature mechanisms and cooling strategies
Protocols, risk factors, and drug interventions
Intraoperative considerations
Post-resuscitation cooling
ICU management.